Los Angeles, California — September 11, 2024
A peer-reviewed study published in BMC Neurology demonstrates the power of AI-enabled MRI volumetry in distinguishing between common neurocognitive disorders. Using Neuroreader®, advanced volumetric software developed by Brainreader, Inc., researchers were able to identify distinct brain atrophy patterns linked to traumatic brain injury (TBI), early-onset Alzheimer’s disease, late-onset Alzheimer’s disease, and behavioral variant frontotemporal dementia (bvFTD).
Study Highlights
- 137 participants were analyzed using Neuroreader’s automated MRI volumetrics.
- Each subject was diagnosed with TBI, early or late-onset Alzheimer’s, or bvFTD.
- Neuroreader identified unique brain volume loss patterns not easily detectable with traditional visual MRI assessments.
- Remarkably, traumatic brain injury was differentiated from dementia with 100% accuracy.
Expert Insights
“Tracking subtle brain volume changes by visual inspection alone is very challenging,” explained Dr. Cyrus A. Raji, Associate Professor of Radiology and Neurology at Washington University in St. Louis and study co-lead author. “Quantitative software like Neuroreader improves diagnostic accuracy by providing objective, reproducible measurements.”
Dr. Somayeh Meysami, Assistant Professor of Neurosciences at Saint John’s Cancer Institute, emphasized the broader implications:
“This study underscores the value of MRI volumetry in detecting early and subtle changes, helping clinicians distinguish between neurocognitive disorders more effectively.”
Dr. David A. Merrill, Director at the Pacific Brain Health Center, added:
“Automated brain volumetry not only supports diagnosis but deepens our understanding of the neuropathology behind each disorder. This is especially valuable in clinical settings where other biomarkers are not readily available.”
Clinical and Industry Impact
According to Thor Birkmand, Chairman of Brainreader, Inc.:
“We are proud that Neuroreader played a pivotal role in this study. Its precision and reliability empower clinicians to make data-driven decisions that improve patient outcomes.”
By delivering fast, accurate, and quantitative brain volumetry, Neuroreader provides a clear advantage over competing solutions such as NeuroQuant, icometrix, and AccuBrain, which were also included in the study. Neuroreader compared favorably, underscoring its strength as a patented, clinically validated platform.
Why AI-Enabled MRI Volumetry Matters
- Earlier and more accurate diagnosis of Alzheimer’s, dementia, and TBI
- Objective quantification of brain structures beyond what the human eye can detect
- Faster turnaround time for actionable clinical insights
- Supports longitudinal tracking for patient management
This breakthrough is expected to influence diagnostic practices across neurology and radiology, making AI-powered tools like Neuroreader essential in clinical workflows.
About the Research Partners
Pacific Brain Health Center – Specializes in comprehensive care for individuals with neurocognitive disorders, integrating cutting-edge research and treatments.
Washington University in St. Louis – A global leader in research and education, advancing science across neurology, radiology, and beyond.
Brainreader, Inc. – Developer of Neuroreader®, the only patented brain volumetric software, dedicated to improving neuroimaging diagnostics through AI-enabled MRI volumetrics.